Abstract
Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.
Original language | English (US) |
---|---|
Pages (from-to) | 160-162 |
Number of pages | 3 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 50 |
Issue number | 2 |
DOIs | |
State | Published - 2002 |
Externally published | Yes |
Keywords
- DNA repair
- O-Alkylguanine-DNA alkyltransferase
- Phase II trial
- Renal cell cancer
ASJC Scopus subject areas
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)